Treatment Intensification in Germ-Cell Tumours

  • Jean-Pierre Droz
  • Pierre Biron
  • Stéphane Culine
  • Andrew Kramar


Germ-cell tumours are rare diseases. However they occur in young patients and their prognosis was unfavourable before the introduction of cisplatin in chemotherapy regimens. Cisplatin based chemotherapy followed by the surgical removal of residual disease is the standard treatment of these tumours (1). Different prognostic classifications or models allow to assign patients in good-risk or poor-risk groups (2). The standard chemotherapy regimen in the good-risk patients group is either three cycles of a combination of cisplatin, etoposide and bleomycin (BEP) or four cycles of combination of etoposide and cisplatin (EP) (1).


Testicular Cancer Complete Remission Rate Autologous Bone Marrow Transplantation Dose Intensification Germ Cell Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1-.
    LH Einhorn Treatment of testicular cancer: a new and improved model. JClin Oncol 8: 1777–1781 1990.Google Scholar
  2. 2-.
    JP Droz, A Kramar, A Rey. Prognostic factors in metastatic disease. Sem Oncol 19: 181–189 1992.Google Scholar
  3. 3-.
    PJ Loehrer, R Lauer, BJ Roth, SD Williams, LA Kalasinskl, LH Einhorn. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Int Med 109: 540–546 1988.CrossRefPubMedGoogle Scholar
  4. 4-.
    JP Droz, A Kramar, C Nichols, H Schmoll, A Auperin, A Harstrick, L Einhorn. Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: assignment of prognostic groups. (abstract) Proc Am Soc Clin Oncol 12: 229, 1993.Google Scholar
  5. 5-.
    W Hryniuk, H Bush. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1288 1984.PubMedGoogle Scholar
  6. 6-.
    G Stoter, Dth Sleijfer, WW Ten Bokkel Huinink, SB Kaye, WG Jones, AT Van Oosterom, CPJ Vendrik, P Spaander, M De Pauw, R Sylvester. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC genitourinary tract cancer cooperative group. J Clin Oncol 4: 1199–1206 1986.PubMedGoogle Scholar
  7. 7-.
    LH Einhorn, SD Williams. Chemotherapy of disseminated testicular cancer. Cancer 46: 1339–1344 1980.CrossRefPubMedGoogle Scholar
  8. 8-.
    ML Samuels, VJ Lanzottl, PY Holoye, LE Boyle, TL Smith, DE Johnson. Combination chemotherapy in germinal cell tumors. Cancer Treat Rev 3: 185–204 1976.CrossRefPubMedGoogle Scholar
  9. 9-.
    MK Samson, SE Rivkin, SE Jones, JJ Costanzi, AF Lobuglio, RL Stephens, Eagehan, GD Cummings. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 53: 1029–1035 1984.CrossRefPubMedGoogle Scholar
  10. 10-.
    RF Ozols, DC Ihde, WM Linehan, J Jacob, Y Ostchega, RC Young. A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis non-seminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040 1988.PubMedGoogle Scholar
  11. 11-.
    CR Nichols, SD Williams, PJ Loehrer, FA Greco, ED Crawford, J Weetlaufer, ME Miller, A Bartolucci, L Schacter, LH Einhorn. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a southeastern cancer study group and southwest oncology group protocol. J Clin oncol 9: 1163–1172 1991.PubMedGoogle Scholar
  12. 12-.
    PJ Loehrer, SD Williams, LH Einhorn. Testicular cancer: the quest continues. J Natl Cancer Inst 80: 1373–1382 1988.CrossRefPubMedGoogle Scholar
  13. 13-.
    JN Wettlaufer, AS Feiner, WA Robinson. Vincristine, cisplatin and bleomycin with surgery in the management of advanced metastatic non-seminomatous testis tumours. Cancer 53: 203–209 1984.CrossRefPubMedGoogle Scholar
  14. 14-.
    A Horwich, M Brada, J Nicholls, G Jay, WF Hendry, DP Dearnaley, MJ Peckham. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 25: 177–184 1989.CrossRefPubMedGoogle Scholar
  15. 15-.
    A Horwich, DP Dearnaley, A Norman, J Nicolls, WF Hendry. Accelerated chemotherapy for poor prognosis germ cell tumours. Eur J Cancer 30A: 1607–1611, 1994.CrossRefPubMedGoogle Scholar
  16. 16-.
    JP Droz, S Culine, B Bui, R Delva, A Caty, M Mousseau, MH Filippi, B Minier. Shortly recycled, intensive alternating, bleomycin containing chemotherapy in heavily pretreated germ cell tumors: an effective strategy, (abstract) Ann Oncol 5: 68, 1994.Google Scholar
  17. 17-.
    E Cvitkovic (personal communication).Google Scholar
  18. 18-.
    C Blanke, P Loehrer, L Einhorn, C Nichols. A phase II study of VP-16 plus ifosfamide plus cisplatin plus vinblastine plus bleomycin (VIP/VB) with filgrastim for advanced stage testicular cancer. (abstract) Proc Am Soc Clin Oncol 13: 234, 1994.Google Scholar
  19. 19-.
    C Bokemeyer, HJ Schmoll. Treatment of advanced germ cell tumours by dose intensified chemotherapy with hematopoietic growth factors or peripheral blood stem cells. Eur Urol 23: 223–230 1993.PubMedGoogle Scholar
  20. 20-.
    SB Kaye, GM Mead, S Fossa, M Cullen, R De Wit, I Bodrogi, C Van Groeningen, R Sylvester, S Stemming, K Vermeylen, E Lallemand, P De Mulder. An MRC/EORTC randomised trial in poor prognosis metastatic teratoma, comparing BEP with BOP-VIP. (abstract) Proc Am Soc Clin Oncol 14: 246, 1995.Google Scholar
  21. 21-.
    JP Droz, JL Pico, A Kramar. Role of autologous bone marrow transplantation in germ-cell cancer. Urol Clin North Am 20: 161–171 1993.PubMedGoogle Scholar
  22. 22-.
    CR Nichols, G Tricot, SD Williams, K Van Besien, PJ Loehrer, BJ Roth, L akard, R Hoffman, R Goulet, SN Wolff, L Giannone, J Greer, LH Einhorn, J Jansen. Dose-intensive chemotherapy in refractory germ cell cancer — A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932–939 1989.PubMedGoogle Scholar
  23. 23-.
    R Motzer, SC Gulati, WP Tong, C Menendez-Botet, P Lyn, M Mazumbar, V Vlamls, S Lin, G Bosl. Phase I trial with pharmacokinetic analysis of high-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer 53: 3730–3735 1993.Google Scholar
  24. 24-.
    A Ibrahim, E Zambon, JH Bourhis, M Ostronoff, F Beaujean, P Viens, C Lhomme, M Chazard, D Maraninchi, M Hayat, JP Droz, JL Pico. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer 29A: 1398–1403, 1993.CrossRefPubMedGoogle Scholar
  25. 25-.
    W Linkesch, HT Greinix, P Hocker, M Krainer, A Wagner. Longterm follow up of phase I/II trial of ultra-high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. (abstract) Proc Am Soc Clin Oncol 12: 232, 1993.Google Scholar
  26. 26-.
    W Siegert, J Beyer, I Strohscheer, H Baurmann, H Oettle, J Zingsem, R Zimmermann, C Bokemeyer, HJ Schmoll, D Huhn. High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 12: 1223–1231 1994.PubMedGoogle Scholar
  27. 27-.
    JP Lotz, D Machover, B Malassagne, B Hingh, R Donsimoni, Y Gumus, J Gerota, Y Lam, M Tulliez, H Marsiglia, S Mauban, V Izrael. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 9: 1860–1870 1991.PubMedGoogle Scholar
  28. 28-.
    JP Lotz, T Andre, R Donsimoni, C Firmin, C Bouleuc, H Bonnak, Z Merad, A Esteso, J Gerota, V Izrael. High dose chemotherapy with ifosfamide, carboplatin and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 75: 874–885 1995.CrossRefPubMedGoogle Scholar
  29. 29-.
    JP Droz, A Kramar, JL Pico. Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Eur J Cancer 29A: 818–821, 1993.CrossRefPubMedGoogle Scholar
  30. 30-.
    JP Droz, JL Pico, M Ghosn, A Kramar, A Rey, M Ostronoff, D Baume. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. Bull Cancer 79: 497–507 1992.PubMedGoogle Scholar
  31. 31-.
    P Biron, D Berton, C Terret, JP Droz. Long term results of high-dose chemotherapy (HDCT) and autologous bone-marrow transplantation (ABMT) in poor-risk and relapsed germ-cell tumors (GCT). (abstract) Proc Am Soc Clin Oncol 14: 320, 1995.Google Scholar
  32. 32-.
    RJ Motzer, M Mazumdar, SC Gulati, DF Bajorin, P Lyn, V Vlamis, GJ Bosl. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85: 1828–1835 1993.CrossRefPubMedGoogle Scholar
  33. 33-.
    JP Droz, JL Pico, P Biron, P Kerbrat, H Cure, JF Heron, C Chevreau, B Chevallier, P Fargeot, J Bouzy, A Kramar. No evidence of a benefit of early intensified chemotherapy (HDCT) with autologous bone marrow transplantation (ABMT) in first line treatment of poor risk non seminomatous germ cell tumors (NSGCT): preliminary results of a randomized trial. (abstract) Proc Am Soc Clin Oncol 11: 197, 1992.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Jean-Pierre Droz
    • 1
  • Pierre Biron
    • 1
  • Stéphane Culine
    • 2
  • Andrew Kramar
    • 3
  1. 1.Department of Medical OncologyCentre Léon BérardLyon cedex 08France
  2. 2.Centre Val d’Aurelle Paul-LamarqueMontpellier cedex 5France
  3. 3.Department of BiostatisticsInstitut Gustave RoussyVillejuif cedexFrance

Personalised recommendations